ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 277 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.78 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $277,620 | +23.4% | 8,400 | +71.4% | 0.00% | +50.0% |
| Q1 2022 | $225,000 | -30.8% | 4,900 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $325,000 | -18.8% | 4,900 | -23.4% | 0.00% | -50.0% |
| Q3 2021 | $400,000 | -51.7% | 6,400 | -36.0% | 0.00% | -50.0% |
| Q2 2021 | $828,000 | +22.5% | 10,000 | -2.0% | 0.01% | +14.3% |
| Q1 2021 | $676,000 | -16.9% | 10,200 | -3.8% | 0.01% | -22.2% |
| Q4 2020 | $813,000 | +38.7% | 10,600 | -22.1% | 0.01% | +28.6% |
| Q3 2020 | $586,000 | -27.8% | 13,600 | -27.7% | 0.01% | -30.0% |
| Q2 2020 | $812,000 | +168.9% | 18,800 | +79.0% | 0.01% | +150.0% |
| Q1 2020 | $302,000 | -20.7% | 10,500 | +75.0% | 0.00% | 0.0% |
| Q4 2019 | $381,000 | -37.5% | 6,000 | -73.9% | 0.00% | -42.9% |
| Q2 2019 | $610,000 | +56.0% | 23,000 | +8.0% | 0.01% | +40.0% |
| Q1 2019 | $391,000 | -6.5% | 21,300 | -2.3% | 0.01% | 0.0% |
| Q3 2018 | $418,000 | – | 21,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Financial Corp/CA | 820,320 | $20,836,128 | 14.83% |
| Aquilo Capital Management, LLC | 1,018,474 | $25,869,240 | 10.72% |
| Rokos Capital Management LLP | 1,675,921 | $41,537,702 | 3.07% |
| COMMODORE CAPITAL LP | 575,000 | $14,605,000 | 2.22% |
| Privium Fund Management B.V. | 259,036 | $6,579,514 | 2.21% |
| JOHNSON & JOHNSON | 247,598 | $6,288,989 | 2.05% |
| WEALTH EFFECTS LLC | 156,810 | $3,982,976 | 2.04% |
| M28 Capital Management LP | 67,400 | $1,711,960 | 1.94% |
| Evolutionary Tree Capital Management, LLC | 51,878 | $1,317,701 | 1.83% |
| Avidity Partners Management LP | 1,741,300 | $44,229,020 | 1.47% |